Drug Screen 9 Panel, Serum or Plasma - Immunoassay Screen with Reflex to Mass Spectrometry Confirmation/Quantitation
0092420
Ordering Recommendation
 
Mnemonic
DRUG SCRSP
Methodology
Qualitative Enzyme-Linked Immunosorbent Assay/ Quantitative Gas Chromatography-Mass Spectrometry/Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Sun-Sat
Reported
1-2 days
Confirmation: 1-4 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
  
Collect
Gray (sodium fluoride/potassium oxalate). Also acceptable: Plain red, green (sodium heparin), lavender (EDTA), or pink (K2EDTA).  
Specimen Preparation
Remove plasma from cells ASAP or within 2 hours of collection. Transfer 4 mL plasma to an ARUP Standard Transport Tube. (Min: 3 mL) Also acceptable: Serum.  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Specimens exposed to repeated freeze/thaw cycles. Separator tubes. Plasma or whole blood collected in lt. blue (sodium citrate).  
Remarks
Cocaine and cocaethylene are more stable in fluoride-preserved plasma than serum.  
Stability
After separation from cells: Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 3 years  
Reference Interval
 
 
Drugs Covered and Cutoff Concentrations
Drugs/Drug Classes Screen
Amphetamines 30 ng/mL
Methamphetamine 30 ng/mL
Barbiturates 75 ng/mL
Benzodiazepines 75 ng/mL
Cannabinoids 30 ng/mL
Cocaine 30 ng/mL
Methadone 40 ng/mL
Opiates 30 ng/mL
Oxycodone 30 ng/mL
Phencyclidine 15 ng/mL
Propoxyphene 75 ng/mL
Interpretive Data
Drugs/Drug classes reported as "Positive" are automatically reflexed to mass spectrometry confirmation/quantitation. An unconfirmed positive immunoassay screen result may be useful for medical purposes but does not meet forensic standards. The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies within a drug class. Specimens for which drugs or drug classes are detected by the screen are automatically reflexed to a second, more specific technology (GC/MS and/or LC-MS/MS). The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

For medical purposes only; not valid for forensic use.

See Compliance Statement B: www.aruplab.com/CS
Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
 
Note
Screen-positive specimens are automatically confirmed by GC/MS and/or LC-MS/MS; additional charges may apply.
CPT Code(s)
80101 x9 (HCPCS:G0431); if positive add appropriate CPT code(s): 82542; 82520; 83925; 83992; 82145; 82205; 80154; 83840; 83925
Components
Component Test Code*Component Chart NameLOINC
0092419Drug Screen Comments, Serum or Plasma48767-8
0092421Cannabinoids, Serum or Plasma8172-9
0092422Cocaine, Serum or Plasma8191-9
0092423Opiates, Serum or Plasma8219-8
0092424Phencyclidine, Serum or Plasma8236-2
0092425Amphetamines, Serum or Plasma8149-7
0092426Barbiturates, Serum or Plasma20421-4
0092427Benzodiazepines, Serum or Plasma46976-7
0092428Methadone, Serum or Plasma59705-4
0092429Propoxyphene, Serum or Plasma59734-4
0092430Oxycodone, Serum or Plasma13576-4
0093414Methamphetamine, Serum or Plasma3777-0
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Pain Management